Antibody Particle Size Distribution and Aggregation Analysis
In biopharmaceutical R&D and production, the particle size distribution and aggregation state of antibodies are key quality control indicators. The particle size distribution of antibodies directly affects the stability and efficacy of drugs, while the presence of aggregates may lead to immunogenic reactions and reduce the safety and effectiveness of drugs. CD BioSciences is committed to providing advanced biophysical technologies for detailed analysis of antibody particle size distribution and aggregation to ensure that your biologics meet the highest quality standards.
Background
Currently, monoclonal antibodies have become the main drugs for the treatment of many diseases such as cancer, allergies, and autoimmune diseases. With the continuous development of such products, how to improve the stability of drug formulations, especially to prevent protein aggregation during manufacturing, transportation, storage, and delivery, is a key challenge. Therefore, the detection of antibody aggregation states and particles is crucial. Biophysical technology is a powerful tool that can accurately measure and analyze the particle size distribution and aggregation state of antibodies to support antibody preparation.
Figure 1. An accelerated antibody aggregation test based on time sequenced dynamic light scattering. (Conner C G, et al., 2022)
Our Services
- Dynamic Light Scattering (DLS)
At CD BioSciences, we use advanced DLS technology to provide customers with accurate antibody particle size distribution and aggregation state analysis. DLS technology is fast and efficient and can provide detailed particle size distribution data in a short time. Our services include measuring the average particle size and size distribution of antibody particles, identifying and quantifying antibody aggregates in samples, and monitoring the stability of antibodies under different environmental conditions to ensure the stability and effectiveness of antibodies during storage and transportation.
- Static Light Scattering (SLS)
Our team uses SLS technology to provide accurate antibody molecular weight determination and intermolecular interaction analysis. SLS technology can measure the molecular weight and second Virial coefficient (A2) of molecules in solution, thereby gaining in-depth insights into the solution behavior of antibodies. Our services include accurately determining the molecular weight of antibodies, identifying and quantifying aggregates in antibody samples, and evaluating the interactions between antibody molecules through A2 values, helping customers optimize antibody formulations and improve drug stability and efficacy.
- Multi-angle Light Scattering (MALS)
We use MALS technology to provide comprehensive antibody molecular weight and particle size distribution analysis. MALS technology combines the advantages of DLS and SLS and can measure the molecular weight distribution of antibody samples with high precision, and characterize the type and number of aggregates in antibody samples in detail. Our services are suitable for the fine characterization of multi-component mixtures or complex antibody samples, providing customers with reliable experimental data and scientific basis, and assisting the research and development and quality control of antibody drugs.
Application Areas
- Drug R&D. Our services support the entire drug development process from early screening to preclinical development.
- QC. Our biophysical analysis platform is used for quality control during the production process to ensure product consistency and stability.
- Formulation development. Our technology supports the optimization of antibody formulations to improve drug stability and efficacy.
Our Advantages
- Full-service platform. Our platform is equipped with state-of-the-art instruments to ensure data accuracy and reliability.
- Strong technical support. Our team is composed of experienced biophysicists with rich experience in antibody analysis.
- Customization. We will provide customized analysis solutions based on customer needs to ensure that specific research and development goals are met.
With the most comprehensive technology platform, CD BioSciences is committed to providing customers with the highest quality antibody analysis services to facilitate the development of antibody drugs. If you are interested in our services, please contact us for more details.
Reference
- Conner C G, McAndrew J, Menegatti S, et al. (2022). An accelerated antibody aggregation test based on time sequenced dynamic light scattering[J]. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 653: 129833.
For research use only, not
intended for any clinical use.
Related Services
